Development of classification and response criteria for rheumatic diseases

Authors

  • CLASSIFICATION AND RESPONSE CRITERIA SUBCOMMITTEE OF THE AMERICAN COLLEGE OF RHEUMATOLOGY COMMITTEE ON QUALITY MEASURES

    Corresponding author
    • Address correspondence to Daniel H. Solomon, MD, MPH, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120
    Search for more papers by this author
    • Members of the Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures: Jasvinder A. Singh, MD, MPH (Co-Chair), Daniel H. Solomon, MD, MPH (Co-Chair), Maxime Dougados, MD, David Felson, MD, MPH, Gillian Hawker, MD, MPH, Patricia Katz, PhD, Hal Paulus, MD, Carol Wallace, MD.


  • The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.

Abstract

Relevance to the clinician. Clinicians already know that not all patients who are diagnosed with rheumatic diseases really have them. Moreover, determining which patients have improved and by how much is also difficult. Classification criteria allow clinical researchers to recruit patients with similar diseases (e.g., rheumatoid arthritis or systemic lupus erythematosus) into studies. Response criteria help to determine whether treatments really work, i.e., whether they actually produce clinically important improvement. As the science of clinical research advances, we must update our standards for considering classification and response criteria. In this editorial, members of the American College of Rheumatology (ACR) Subcommittee on Classification and Response Criteria describe the purpose of criteria sets, their development and validation, and the role of the ACR in adopting them.

Ancillary